Results 61 to 70 of about 259,208 (317)

DNA methylation and expression of MAPRE3 affect overall survival of early‐stage non‐small cell lung cancer patients

open access: yesMolecular Oncology, EarlyView.
Both cg12821679MAPRE3 methylation and MAPRE3 expression are significantly associated with overall survival (OS) of non‐small cell lung cancer. Meanwhile, MAPRE3 expression significantly modified the effect of smoking cessation on OS. Smoking cessation benefits OS merely for patients with high MAPRE3 expression.
Chao Chen   +14 more
wiley   +1 more source

Natural killer cells in asthma [PDF]

open access: yesCurrent Opinion in Allergy & Clinical Immunology, 2017
Purpose of review This review article discusses current knowledge on natural killer (NK) cells in asthma. Recent findings It is now well accepted that NK cell activities go beyond cancer immune surveillance and antiviral defense.
openaire   +2 more sources

Natural killer cell/epithelial interactions [PDF]

open access: yes, 2010
Natural killer (NK) cells and epithelial cells can interact closely at sites of inflammation, contributting to the pathogenesis of inflammatory diseases such as contact hypersensitivity.
Ralf Paus   +5 more
core   +1 more source

Low-intensity Pulsed Ultrasound Enhances NK Cell Adoptive Therapy by Modulating the Wnt/β-catenin Signaling Pathway

open access: yesBIO Integration
Natural killer cell adoptive therapy is a novel immunotherapy strategy for the treatment of multiple refractory tumors, including ovarian cancer. However, natural killer cells’ anti-tumor effectiveness is limited by their viability and cytotoxicity.
Renjie Feng   +3 more
doaj   +1 more source

Invariant Natural Killer T Cells

open access: yesAntibodies, 2013
Invariant Natural killer T cell (iNKT cells) are a subset of T cells, which are narrowly defined as a T cell lineage expressing a semi-invariant CD1d-restricted T cell Receptors (TCRs) composed by Vα24-Jα18/Vβ11 in human, and Vα14-Jα18/Vβ8,Vβ7, and Vβ2 ...
Antonella Cianferoni
doaj   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

open access: yesMolecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura   +19 more
wiley   +1 more source

Insulin-like growth factor I is an independent coregulatory modulator of natural killer (NK) cell activity. [PDF]

open access: yes, 1996
We aimed to investigate the natural killer (NK) cell activity in hGH-deficient adults and to analyze the effect of insulin-like growth factor (IGF)-I in uivo and in vitro on NK cell activity.
Pachmann, K.   +4 more
core   +1 more source

Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer

open access: yesMolecular Oncology, EarlyView.
Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola   +11 more
wiley   +1 more source

Influence of Cytokines and Autologous Lymphokine-Activated Killer Cells on Leukemic Bone Marrow Cells and Colonies in AML [PDF]

open access: yes, 2001
We have already shown that cytokine cocktails (IL-1 beta, IL-3, IL-6, SCF, GM-CSF) and/or lymphokine-activated killer (LAK) cells can reduce the amounts of clonal, CD34-positive mononuclear bone marrow cells (BM-MNC) in acute myeloid leukemia (AML).
Gerhartz, Helmut Heinrich   +2 more
core   +1 more source

Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study

open access: yesHaematologica, 2017
Despite persistence of leukemic stem cells, patients with chronic myeloid leukemia who achieve and maintain deep molecular responses may successfully stop the tyrosine kinase inhibitor imatinib.
Delphine Rea   +20 more
doaj   +1 more source

Home - About - Disclaimer - Privacy